Shrinking Healthcare Budgets to Carve Way for Biosimilars
In case of such a situation, Biosimilar drugs hold the promise to help keep biologic prices--which can be as high as US$ 1,000 per pill, under control. The potential cost savings of biosimilar drugs is huge; a Rand Institute study estimates that widespread adoption could reduce drug costs by as much as US$ 66 Billion over the next decade. According to the Congressional Budget Office, biosimilars are expected to save US$ 13 Billion over the next 10 years.
View full press release